CorDX obtains CE Mark for test for COVID-19, flu A/B, RSV

LabPulse.com staff writers
Jun 2, 2022
2021 01 11 17 03 4617 Covid Diagnostic Test Kit 400

CorDx this week announced it has received the CE Mark for a test that simultaneously detects influenza A, influenza B, COVID-19, and respiratory syncytial virus (RSV).

"As COVID-19 infection prevention measures relax globally, COVID and other viral infections are projected to rise," CorDx founder and CEO Jeff Yufeng Li said in a statement.

The company's Influenza A/B+COVID-19/RSV Combo Ag Test enables the detection of all four conditions in a single self-administered test.

Latest in Influenza
Colorized transmission electron micrograph of avian influenza A H5N1 virus particles shown in yellow.
Alveo Technologies to develop avian influenza A(H5) test with CDC
November 14, 2024
Body composition in patients treated with Ozempic
Sponsored
Body composition in patients treated with Ozempic
September 20, 2024
Lab Virus Bacteria Research Social
Alveo develops rapid test for avian flu
July 23, 2024
Colorized transmission electron micrograph of avian influenza A H5N1 virus particles (yellow), grown in Madin-Darby Canine Kidney (MDCK) epithelial cells (blue). Microscopy by CDC; repositioned and recolored by NIAID.
BARDA awards Moderna $176M for pandemic flu vaccine development
July 2, 2024
Related Stories
Influenza Virus Social
FDA Submission
CorDx submits EUA application for COVID-19/influenza rapid test
2022 05 26 14 35 1895 Monkeypox Virus 400
CE mark
CorDx obtains CE Mark for monkeypox tests
2020 04 16 18 56 8041 Virus Coronavirus Sars Co V 2 400
Influenza
Applied BioCode receives EUA for SARS-CoV-2 combo assay
Body composition in patients treated with Ozempic
Sponsor Content
Body composition in patients treated with Ozempic
More in Influenza
Alveo Technologies to develop avian influenza A(H5) test with CDC
By LabPulse.com staff writers
Under the agreement with the CDC, Alveo Technologies will develop a rapid diagnostic to detect and differentiate between influenza A and B and influenza A/H5, also known as the avian influenza subtype, in humans.
November 14, 2024
Colorized transmission electron micrograph of avian influenza A H5N1 virus particles shown in yellow.
Roche launches diagnostic test for 12 respiratory viruses
By LabPulse.com staff writers
Roche Diagnostics has launched its first test using its new high-throughput technology that enables users of Roche's Cobas analyzers to simultaneously test for 12 respiratory viruses.
September 26, 2024
Roche Aacc 2019 Social
Alveo develops rapid test for avian flu
By LabPulse.com staff writers
Diagnostics firm Alveo Technologies has developed a rapid, point-of-need diagnostic for avian influenza that can detect the H5N1 variant based on sequences published from recent human and cattle infections.
July 23, 2024
Lab Virus Bacteria Research Social
BARDA awards Moderna $176M for pandemic flu vaccine development
By LabPulse.com staff writers
The Biomedical Advanced Research and Development Authority (BARDA) has awarded Moderna approximately $176 million for the development of an mRNA-based pandemic influenza vaccine.
July 2, 2024
Colorized transmission electron micrograph of avian influenza A H5N1 virus particles (yellow), grown in Madin-Darby Canine Kidney (MDCK) epithelial cells (blue). Microscopy by CDC; repositioned and recolored by NIAID.
NIH starts early-phase trial of second-generation universal flu vaccine candidate
By Nick Paul Taylor
The U.S. National Institutes of Health (NIH) has begun an early-phase clinical trial of its second-generation universal flu vaccine candidate.
September 20, 2023
Needle Shot Vaccine Teenager Social
Moderna’s mRNA flu shot yields promising results in phase III trial
By LabPulse.com staff writers
Moderna announced that its mRNA flu shot that is in development has met its primary endpoints in a phase III trial, generating a stronger immune response than a commercially available flu vaccine.
September 15, 2023
Vaccine Injection Woman Social
COVID-19 still associated with higher death risk than flu
By Elissa Wolfson
VA hospital patients with COVID-19 had a higher risk of death than seasonal influenza patients from fall 2022 to winter 2023.
April 11, 2023
Influenza Virus Social
FDA grants 510(k) clearance to DiaSorin for COVID-19 and flu A/B assay
By Leo O'Connor
The test detects and differentiates influenza A, influenza B, and SARS-CoV-2 viruses to help ensure physicians can recommend the most appropriate treatment for each patient.
March 20, 2023
Fda Button Social
Cepheid says its influenza assays mitigate impact of mutational drift seen in some tests
By LabPulse.com staff writers
Two mutations in the matrix genes of the human influenza A virus have been reported to cause matrix gene target failure for several commercial diagnostic tests.
December 8, 2022
Flu Season Ahead Social
Reagent supplier launches antigens for Southern Hemisphere's 2023 flu season
By LabPulse.com staff writers
The hemagglutinin and neuraminidase antigens were developed in response to flu vaccine formulations the World Health Organization selected for development in the Southern Hemisphere.
November 21, 2022
Flu Season Ahead Social
Virax introduces rapid test kit for RSV, influenza A/B, COVID-19
By LabPulse.com staff writers
Virax Biolabs announced the distribution of a rapid antigen test kit capable of detecting when individuals have been infected with RSV, Influenza A/B, or COVID-19.
November 3, 2022
Respiratory Syncytial Virus Cdc Social
University of Illinois spinout Shield T3 launches saliva-based PCR test for COVID, flu, RSV
By LabPulse.com staff writers
Shield T3, a spinout of the University of Illinois, will offer a triple-virus PCR test kit, in anticipation of increased cases of COVID-19, flu, and RSV this winter.
October 25, 2022
Covid Diagnostic Test Kit
Page 1 of 7
Next Page